NextCure, Inc.
NASDAQNXTC heads into its May 11 earnings call with the stock already trading on partial information — Q1 results published after the bell Thursday showed EPS of -$1.87, beating the -$2.12 estimate, alongside a significant pipeline update. The clinical newsflow has been the dominant driver. On May 4, NextCure and partner Simcere Zaiming announced the initiation of the dose optimization…
Snapshot as of 23 Jun 2026
NXTC heads into its May 11 earnings call with the stock already trading on partial information — Q1 results published after the bell Thursday showed EPS of -$1.87, beating the -$2.12 estimate, alongside a significant…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NXTC — free to start on ORTEX.
Sign up for free →Open NXTC on ORTEX